![Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial) | Journal of Nuclear Medicine Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial) | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/early/2023/08/31/jnumed.123.265853/F1.large.jpg)
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial) | Journal of Nuclear Medicine
Nine years ago this week I underwent a double mastectomy. Picture one is me with my oncological surgeon Dr. Michelle Specht. The rest of… | Instagram
Dwight Specht - Vice President, Digital Transformation & Strategy, Bridgestone Mobility Solutions - Bridgestone Americas | LinkedIn
![Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial) | Journal of Nuclear Medicine Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial) | Journal of Nuclear Medicine](https://jnm.snmjournals.org/sites/default/files/highwire/jnumed/64/11.cover-source.jpg)